Biohaven Pharmaceutical(BHVN.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Biohaven Pharmaceutical
BHVN.US
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson’s disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin’s lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors.
1.955 T
BHVN.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sector Update: Health Care Stocks Rise in Afternoon Trading

    Health care stocks experienced a rise in afternoon trading, with the NYSE Health Care Index up 1%. Dr. Reddy's Laboratories plans to sell a generic version of Novo Nordisk's Ozempic, leading to a 2.5% gain in its shares. Johnson & Johnson's full-year sales outlook exceeded expectations, despite a 0.8% drop in shares. Merck is collaborating on a $30 million program to update its Ebola vaccine, resulting in a 1.9% share increase. CVS Health faces a class action regarding higher fees for tobacco users, with shares up 2.1%.

    fidelity·
    US
    NVO
    +0.04%
    fidelity·
    US
    NVO
    +0.04%

    Biohaven shares are trading higher after RBC Capital upgraded the stock from Sector Perform to Outperform and raised its price target from $9 to $22.

    benzinga_article·
    US
    BHVN
    -2.76%
    benzinga_article·
    US
    BHVN
    -2.76%

    This Albemarle Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

    Top Wall Street analysts have upgraded several stocks. Keybanc's Jeffrey Hammond upgraded Watts Water Technologies (WTS) to Overweight with a $340 target. RBC's Leonid Timashev upgraded Biohaven (BHVN) to Outperform, raising the target from $9 to $22. Raymond James' Olivia Tong upgraded Ulta Beauty (ULTA) to Strong Buy, increasing the target from $605 to $790. Susquehanna's Chris Rolland upgraded Arm Holdings (ARM) to Positive, maintaining a $150 target. Truist's Peter Osterland upgraded Albemarle (ALB) to Buy, raising the target from $125 to $205.

    benzinga_article·
    US
    WTS
    -1.69%
    US
    ULTA
    +0.35%
    US
    BHVN
    -2.76%
    benzinga_article·
    US
    WTS
    -1.69%
    US
    ULTA
    +0.35%
    US
    BHVN
    -2.76%

    Biohaven (BHVN) Stock Is Trending Overnight — Here's What You Should Know

    Biohaven Ltd. (NYSE:BHVN) shares rose 3.42% in after-hours trading to $12.10 following an SEC filing that included updates on its drug pipeline. The stock closed at $11.70, up 6.65% during regular trading. The company presented data on its drug BHV-1400 at the J.P. Morgan Healthcare Conference, showing promising results in Phase 1 studies. Biohaven expects multiple pivotal results in 2026, but its stock has declined 67.11% over the past year, indicating caution for traders. The current market cap is $1.55 billion, with shares trading closer to recent lows.

    benzinga_article·
    US
    BHVN
    -2.76%
    benzinga_article·
    US
    BHVN
    -2.76%

    U.S. stock market midday update: Biohaven Pharmaceutical up 8.02%, progress in innovative drugs boosts market confidence

    Biohaven Pharmaceutical rose 8.02%; AbbVie rose 0.20%, with a transaction volume of USD 971 million; Moderna rose 2.27%, with a transaction volume of USD 635 million; Biogen fell 4.79%, with a transaction volume of USD 480 million; Amgen rose 0.84%, with a market value of USD 176 billion

    Tracking Unusual Activity·
    US
    BHVN
    -2.76%
    Tracking Unusual Activity·
    US
    BHVN
    -2.76%
    © 2026 Longbridge｜Disclaimer